💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Alkermes plc (ALKS)
« Back to company indexALKS Chatter Timeline
Stock Ticker for ALKS
Most Active Tweeters for ALKS
| User | Tweets |
|---|---|
| @newsfilterio | 11 |
| @FlashAlert_me | 9 |
| @A1Syad | 6 |
| @quantisnow | 4 |
| @otcdynamics | 4 |
Recent Tweets for ALKS
 |
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider Wysenski Nancy: Delivered securities 1,339 of Ordinary Shares at pr… https://t.co/cYElmuKoF8 2:12am |
 |
@newsfilterio $29,605.29 of shares sold by Wysenski Nancy (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/086pJhiDHX 2:12am |
|
@newsfilterio $29,605.29 of shares sold by Snyderman Nancy Lynn Md (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/XpEFyMbcws 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider Wilson Frank Anders: Delivered securities 1,339 of Ordinary Shares… https://t.co/5ELhgJ9LjQ 2:12am |
|
@newsfilterio $29,605.29 of shares sold by Wilson Frank Anders (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/KjjDvFLq7w 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider snyderman nancy lynn MD: Delivered securities 1,339 of Ordinary Sha… https://t.co/HAO1Vrw2sq 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider GAYNOR RICHARD: Delivered securities 1,339 of Ordinary Shares at pr… https://t.co/ESJtFRpHPo 2:12am |
|
@newsfilterio $29,605.29 of shares sold by Gaynor Richard (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/xUMTmkbxSq 2:12am |
|
@newsfilterio $29,605.29 of shares sold by Dixon Wendy L (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/WHbu45mxV1 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider DIXON WENDY L: Delivered securities 1,339 of Ordinary Shares at pri… https://t.co/oFlqEMLFp6 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider ANSTICE DAVID W: Delivered securities 1,339 of Ordinary Shares at p… https://t.co/wxoRsX5REK 2:12am |
|
@newsfilterio $29,605.29 of shares sold by Anstice David W (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/ShxNNUgUay 2:12am |
 |
@quantisnow $ALKS ? SEC Form 4: Cooke Shane converted options into 5,578 units of Ordinary Shares and covered exercise/tax liab… https://t.co/zjboFVqxl8 2:12am |
|
@newsfilterio $64,141.11 of shares sold by Cooke Shane (Director), reported in a new form 4 filed with the SEC $ALKS https://t.co/j6N7L34dxg 2:12am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 4: Insider Cooke Shane: Delivered securities 2,901 of Ordinary Shares at price… https://t.co/pjqGdf9YY6 2:12am |
 |
@Tickeron $ALKS's Aroon indicator drops into Downtrend on December 2, 2021. View odds for this and other indicators:… https://t.co/ksqEpYHuFa December 3rd 2021, 11:12pm |
 |
@otcdynamics $ALKS Our Collective Responsibility to Respond Effectively to the Climate Crisis https://t.co/EXl01IQkr0 December 3rd 2021, 3:12pm |
 |
@A1Syad $ALKS Looks oversold Register for 7-Day Trial Access at https://t.co/4iPw4wpfNW https://t.co/Mv8YKjr3Xb December 3rd 2021, 2:12am |
 |
@Tradingchannels $ALKS looks very ugly. https://t.co/xjchz76cYI December 2nd 2021, 6:12pm |
 |
@DuhBluePrint $ALKS about to be a fallin knife sooner than later December 2nd 2021, 6:12am |
|
@A1Syad $ALKS Looks oversold Register for 7-Day Trial Access at https://t.co/4iPw4wGRcw https://t.co/7goE9cNIIb December 1st 2021, 8:12pm |
 |
@MarcJacksonLA $ALKS Citigroup Initiates Coverage On Alkermes At Neutral, $22 PT https://t.co/xKruSlBFiq December 1st 2021, 3:12pm |
 |
@bthefirsttoknow First out// $ALKS: Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021 https://t.co/JIXojttkMJ December 1st 2021, 3:12pm |
 |
@Jarvis_Alerts $ALKS [Alkermes]: Citigroup Initiates Coverage On Neutral Announces Price Target $22 Sign-up free for beta ver.:… https://t.co/KQ0fHzJ0dZ December 1st 2021, 1:12pm |
 |
@Gambiste1 RT @vtmtrading: Alkermes initiated with a Neutral at Citi $ALKS December 1st 2021, 12:12pm |
 |
@TeamofStockTra $ALKS - Citigroup Initiates Coverage On Alkermes with Neutral Rating, Announces Price Target of $22 December 1st 2021, 12:12pm |
|
@quantisnow $ALKS ? Citigroup initiated coverage on Alkermes with a new price target https://t.co/tLONnUnCnh 45 seconds delayed. December 1st 2021, 11:12am |
|
@newsfilterio $ALKS Citigroup analyst Navann Ty initiates coverage on Alkermes with a Neutral rating and announces Price Target of $22. December 1st 2021, 11:12am |
 |
@vtmtrading Alkermes initiated with a Neutral at Citi $ALKS December 1st 2021, 11:12am |
|
@otcdynamics $ALKS Alkermes in Action: Giving Tuesday https://t.co/BLBmkcxcE9 November 30th 2021, 4:11pm |
 |
@Sanctuary_Bio @adar170 the only thing this company has done right in the last 5 years is swindling $ALKS for Vumerity I'm not su… https://t.co/XWeswNvCYh November 30th 2021, 4:11pm |
|
@A1Syad $ALKS Looks oversold Register for 7-Day Trial Access at https://t.co/4iPw4wGRcw https://t.co/9JrE2eiGeY November 29th 2021, 10:11pm |
|
@otcdynamics $ALKS One Overdose Is Too Many https://t.co/TIqEtAJRhH November 29th 2021, 4:11pm |
 |
@adaam_e $ALKS Was in a good uptrend this year until recently. Testing a good area. Maybe bounce it back up to test the uppe… https://t.co/AZjr8jqNlm November 27th 2021, 11:11pm |
|
@A1Syad $ALKS Looks oversold Register for 7-Day Trial Access at https://t.co/4iPw4wGRcw https://t.co/C3iXUi3OZV November 26th 2021, 9:11pm |
 |
@usasingh1 $ALKS https://t.co/rM9OGZhdvM https://t.co/IaU6JHsW9l November 25th 2021, 5:11pm |
 |
@1stOncology #Alkermes to Take Part in the Fourth Annual Evercore ISI #HealthCONxConference $ALKS https://t.co/FgCXXriVfm November 25th 2021, 7:11am |
|
@quantisnow $ALKS ? SEC Form 3 filed by new insider Laurencin Cato T https://t.co/RA0FPOZvlj 45 seconds delayed. November 25th 2021, 1:11am |
|
@newsfilterio Form 3 (initial statement of beneficial ownership of securities) filed with the SEC $ALKS https://t.co/LYBiJ7LAAh November 25th 2021, 1:11am |
|
@FlashAlert_me $ALKS [15s. delayed] filed SEC form 3: Director LAURENCIN CATO T: https://t.co/iKKyl5bwvV November 25th 2021, 1:11am |
|
@A1Syad $ALKS So easy to trade with the Short / Buy signals. Register for 7-Day Trial Access at https://t.co/4iPw4wGRcw https://t.co/bxbUajxmY5 November 25th 2021, 12:11am |
|
@FlashAlert_me $ALKS [15s. delayed]: Issued Press Release on November 24, 16:00:00: Alkermes to Take Part in the Fourth Annual Eve… https://t.co/adS3MzofDh November 24th 2021, 9:11pm |
 |
@StockNewsBot2 $ALKS Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference https://t.co/x24SLZl6xx November 24th 2021, 9:11pm |
 |
@phasefivebot $ALKS Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference https://t.co/drxK6iswR1 November 24th 2021, 9:11pm |
|
@quantisnow $ALKS ? Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference https://t.co/q1qPGFmEX1 45 seconds delayed. November 24th 2021, 9:11pm |
|
@newsfilterio Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference $ALKS https://t.co/Z6yZgSDd7n November 24th 2021, 9:11pm |
 |
@stock_titan $ALKS Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference https://t.co/kZgkh3VmoZ November 24th 2021, 9:11pm |
|
@otcdynamics $ALKS Alkermes Celebrates National Family Caregivers Month https://t.co/G3koWiEF4u November 24th 2021, 4:11pm |
 |
@excellencia_ltd RT @JDruryPartners: Alkermes adds Cato T. Laurencin (Professor, University of Connecticut) to Board $ALKS #corpgov https://t.co/hnIqtgchh0 November 24th 2021, 8:11am |
 |
@JDruryPartners Alkermes adds Cato T. Laurencin (Professor, University of Connecticut) to Board $ALKS #corpgov https://t.co/HLqZL4moGF November 23rd 2021, 9:11pm |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
DrugPatentWatch Video Training
Decision-making for generic drug entry and branded drug lifecycle management
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
This course answers the following questions to help you adapt:
- ✓ When will key drug patents expire?
- ✓ How can I find, evaluate, and plan for generic market entry opportunities?
- ✓ How can I find proprietary out-of-court settlements and deal terms?